<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1508210937
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VIMPAT 150 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LACOSAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        417.6
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aesica Pharmaceuticals GmbH." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aesica Pharmaceuticals GmbH.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Vimpat is</strong></p><p>Vimpat contains lacosamide. This belongs to a group of medicines called &ldquo;antiepileptic medicines&rdquo;. These medicines are used to treat epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have been given this medicine to lower the number of fits (seizures) you have.</p><p>&nbsp;</p><p><strong>What Vimpat is used for</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vimpat is used in adults, adolescents and children aged 4&nbsp;years and older.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is used:</p><p>&sect;&nbsp;&nbsp;&nbsp; on its own and in association with other antiepileptic medicines to treat a certain type of epilepsy characterised by the occurrence of partial-onset seizure with or without secondary generalisation. In this type of epilepsy, fits first affect only one side of your brain. However, these may then spread to larger areas on both sides of your brain;</p><p>&sect;&nbsp;&nbsp;&nbsp; in association with other antiepileptic medicines to treat primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Do not take Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to lacosamide, or any of the other ingredients of this medicine (listed in section&nbsp;6). If you are not sure whether you are allergic, please discuss with your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a certain type of heart beat problem called second- or third-degree AV block.</p><p>&nbsp;</p><p>Do not take Vimpat if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Vimpat if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have thoughts of harming or killing yourself. A small number of people being treated with antiepileptic medicinal products such as lacosamide have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, tell your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a heart problem that affects the beat of your heart and you often have a particulary slow, fast or irregular heart beat (such as AV block, atrial fibrillation and atrial flutter).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe heart disease such as heart failure or have had a heart attack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are often dizzy or fall over. Vimpat may make you dizzy - this could increase the risk of accidental injury or a fall. This means that you should take care until you are used to the effects of this medicine.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>If you are taking Vimpat, talk to your doctor if you are experiencing a new type of seizure or worsening of existing seizures.</p><p>If you are taking Vimpat and you are experiencing symptoms of abnormal heartbeat (such as slow, rapid or irregular heartbeat, palpitations, shortness of breath, feeling lightheaded, fainting), seek medical advice immediately (see section 4).</p><p><strong>&nbsp;</strong></p><p><strong>Children under 4&nbsp;years</strong></p><p>Vimpat is not recommended for children aged under 4&nbsp;years. This is because we do not yet know whether it will work and whether it is safe for children in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Vimpat</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Vimpat can also affect your heart:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat heart problems;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines which can increase the &ldquo;PR interval&rdquo; on a scan of the heart (ECG or electrocardiogram) such as medicines for epilepsy or pain called carbamazepine, lamotrigine or pregabalin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat certain types of irregular heart beat or heart failure.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you are taking any of the following medicines - this is because they may increase or decrease the effect of Vimpat on your body:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for fungal infections called fluconazole, itraconazole or ketoconazole;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a medicine for HIV called ritonavir;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat bacterial infections called clarithromycin or rifampicin;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a herbal medicine used to treat mild anxiety and depression called St.&nbsp;John&rsquo;s wort.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Vimpat.</p><p>&nbsp;</p><p><strong>Vimpat with alcohol</strong></p><p>As a safety precaution do not take Vimpat with alcohol.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not recommended to take Vimpat if you are pregnant or breast-feeding, as the effects of Vimpat on pregnancy and the unborn baby or the new-born child are not known. Also, it is not known whether Vimpat passes into breast milk. Seek advice immediately from your doctor if you get pregnant or are planning to become pregnant. They will help you decide if you should take Vimpat or not.</p><p>&nbsp;</p><p>Do not stop treatment without talking to your doctor first as this could increase your fits (seizures). A worsening of your disease can also harm your baby.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not drive, cycle or use any tools or machines until you know how this medicine affects you. This is because Vimpat may make you feel dizzy or cause blurred vision.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Taking Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Vimpat twice each day - once in the morning and once in the evening.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Try to take it at about the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the Vimpat tablet with a glass of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may take Vimpat with or without food.</p><p>&nbsp;</p><p>You will usually start by taking a low dose each day and your doctor will slowly increase this over a number of weeks. When you reach the dose that works for you, this is called the &ldquo;maintenance dose&rdquo;, you then take the same amount each day. Vimpat is used as a long term treatment. You should continue to take Vimpat until your doctor tells you to stop.</p><p><strong>&nbsp;</strong></p><p><strong>How much to take</strong></p><p>Listed below are the normal recommended doses of Vimpat for different age groups and weights. Your doctor may prescribe a different dose if you have problems with your kidneys or with your liver.</p><p>&nbsp;</p><p><strong>Adolescents and children weighing 50&nbsp;kg or more and adults</strong></p><p><u>When you take Vimpat on its own</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg twice a day.</p><p>Your doctor may also prescribe a starting dose of 100&nbsp;mg of Vimpat twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg. This will be until you reach a maintenance dose between 100&nbsp;mg and 300&nbsp;mg twice a day.</p><p>&nbsp;</p><p><u>When you take Vimpat with other antiepileptic medicines</u></p><p>The usual starting dose of Vimpat is 50&nbsp;mg twice a day.</p><p>&nbsp;</p><p>Your doctor may increase your twice daily dose every week by 50&nbsp;mg. This will be until you reach a maintenance dose between 100&nbsp;mg and 200&nbsp;mg twice a day.</p><p>&nbsp;</p><p>If you weigh 50&nbsp;kg or more, your doctor may decide to start Vimpat treatment with a single &ldquo;loading&rdquo; dose of 200&nbsp;mg. You would then start your ongoing maintenance dose 12&nbsp;hours later.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescent weighing less than 50&nbsp;kg</strong></p><p>The dose depends on their body weight. They usually start treatment with the syrup and only change to tablets if they are able to take tablets and get the correct dose with the different tablet strengths. The doctor will prescribe the formulation that is best suited to them.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Vimpat than you should </strong></p><p>If you have taken more Vimpat than you should, contact your doctor immediately. Do not try to drive.</p><p>You may experience:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) or being sick (vomiting);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures), heart beat problems such a slow, fast or irregular heart beat, coma or a fall in blood pressure with rapid heartbeat and sweating.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Vimpat </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose within the first 6&nbsp;hours of the scheduled dose, take it as soon as you remember.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose beyond the first 6&nbsp;hours of the scheduled dose, do not take the missed tablet anymore. Instead take Vimpat at the next time that you would normally take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Vimpat</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not stop taking Vimpat without talking to your doctor, as your epilepsy may come back again or become worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor decides to stop your treatment with Vimpat, they will tell you how to decrease the dose step by step.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Nervous system side effects such as dizziness may be higher after a single &ldquo;loading&rdquo; dose.</p><p>&nbsp;</p><p><strong>Talk to your doctor or pharmacist if you get any of the following:</strong></p><p>&nbsp;</p><p><strong>Very common</strong>: may affect more than 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or sick (nausea);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Double vision (diplopia).</p><p>&nbsp;</p><p><strong>Common</strong>: may affect up to 1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short jerks of a muscle or group of muscles (myoclonic seizures);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties in coordinating your movements or walking;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems in keeping your balance, shaking (tremor), tingling (paresthesia) or muscle spasms, falling easily and getting bruises;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Troubles with your memory, thinking or finding words, confusion;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning sensation (vertigo), feeling drunk;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or bowel, diarrhoea;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased feeling or sensitivity, difficulty in articulating words, disturbance in attention;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Noise in the ear such as buzzing, ringing or whistling;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irritability, trouble sleeping, depression;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleepiness, tiredness or weakness (asthenia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, rash.</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate, palpitations, irregular pulse or other changes in the electrical activity of your heart (conduction disorder);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exaggerated feeling of wellbeing, seeing and/or hearing things which are not there;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction to medicine intake, hives;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests may show abnormal liver function, liver injury;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts of harming or killing yourself or attempting suicide: tell your doctor straight away;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling angry or agitated;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal thinking or losing touch with reality;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious allergic reaction which causes swelling of the face, throat, hands, feet, ankles, or lower legs;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal involuntary movements (dyskinesia). &nbsp;</p><p>&nbsp;</p><p><strong>Not known</strong>: frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal rapid heartbeat (ventricular tachyarrhythmia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sore throat, high temperature and getting more infections than usual. Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious skin reaction which may include a high temperature and other flu-like symptoms, a rash on the face, extended rash, swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and a type of white blood cell (eosinophilia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens&ndash;Johnson syndrome), and a more severe form causing skin peeling in more than 30&nbsp;% of the body surface (toxic epidermal necrolysis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsion.</p><p>&nbsp;</p><p><strong>Additional side effects in children </strong></p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in 10&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Runny nose (nasopharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (pyrexia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore throat (pharyngitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eating less than usual.</p><p>&nbsp;</p><p><strong>Uncommon</strong>: may affect up to 1 in 100&nbsp;children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sleepy or lacking in energy (lethargy).</p><p>&nbsp;</p><p><strong>Not known: </strong>frequency cannot be estimated from available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in behaviour, not acting like themselves.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Vimpat contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lacosamide.</p><p>One tablet of Vimpat 50&nbsp;mg contains 50&nbsp;mg lacosamide.</p><p>One tablet of Vimpat 100&nbsp;mg contains 100&nbsp;mg lacosamide.</p><p>One tablet of Vimpat 150&nbsp;mg contains 150&nbsp;mg lacosamide.</p><p>One tablet of Vimpat 200&nbsp;mg contains 200&nbsp;mg lacosamide.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><strong>Tablet core</strong>: microcrystalline cellulose, hydroxypropylcellulose, hydroxypropylcellulose (low substituted), colloidal anhydrous silica, crospovidone (polyplasdone XL-10 Pharmaceutical Grade), magnesium stearate.</p><p><strong>Film-coat</strong>: polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide (E171), colourants*.</p><p><strong>*</strong> The colourants are:</p><p>50&nbsp;mg tablet: red iron oxide (E172), black iron oxide (E172), indigo carmine aluminium lake (E132).</p><p>100&nbsp;mg tablet:<strong><em> </em></strong>yellow iron oxide (E172).</p><p>150&nbsp;mg tablet: yellow iron oxide (E172),<em> </em>red iron oxide (E172), black iron oxide (E172).</p><p>200&nbsp;mg tablet:<em> </em>indigo carmine aluminium lake (E132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	•	Vimpat 50 mg are pinkish, oval film-coated tablets of approximately 10.4 mm x 4.9 mm with a debossed ‘SP’ on one side and ‘50’ on the other side.
•	Vimpat 100 mg are dark yellow, oval film-coated tablets of approximately 13.2 mm x 6.1 mm with a debossed ‘SP’ on one side and ‘100’ on the other side.
•	Vimpat 150 mg are salmon, oval film-coated tablets of approximately 15.1 mm x 7.0 mm with a debossed ‘SP’ on one side and ‘150’ on the other side.
•	Vimpat 200 mg are blue, oval film-coated tablets of approximately 16.6 mm x 7.8 mm with a debossed ‘SP’ on one side and ‘200’ on the other side.

Vimpat is available in packs of 14and 56 film-coated tablets, Vimpat packs are available with standard PVC/PVDC blisters sealed with an aluminium foil. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>UCB Pharma S.A., All&eacute;e de la Recherche 60, B‑1070 Bruxelles, Belgium.</p><p>Tel: +32 2 559 99 99</p><p>Fax: +32 2 559 99 00</p><p>http://www.ucb.com</p><p>&nbsp;</p><p><strong>Batch releaser</strong></p><p>Aesica Pharmaceuticals GmbH, Alfred-Nobel Strasse 10, D-40789 Monheim am Rhein, Germany.</p><p>Tel: +49 2173 335 0000<br />Fax: +49 2173 335 1020<br />info@aesica-pharma.com</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Aesica Pharmaceuticals GmbH, Galileistra&szlig;e 6, 08056 Zwickau, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in {06/2021}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو دواء ڨيمبات؟</strong></p><p dir="RTL">يحتوي دواء ڨيمبات على لاكوساميد.&nbsp; ينتمي هذا الدَّواء إلى مجموعة من الأدوية تُسمى &quot;مضادات الصَّرع&quot;. تستخدم هذه الأدوية في علاج الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لقد تم إعطاؤك هذا الدَّواء لخفض عدد التشنجات (النوبات التشنُّجية) التي تتعرَّض لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيم يستخدم دواء ڨيمبات؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم دواء ڨيمبات في البالغين والمراهقين والأطفال من عمر 4 سنوات وأكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم بمفرده أو بمصاحبة أدوية أخرى مضادة للصرع لعلاج نوع معين من أنواع الصرع يتسم بحدوث نوبة تشنجية تظهر جزئيًّا مع تعميم ثانوي أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في هذا النوع من الصَّرَع، تُؤثر التشنجات أولًا على أحد جانبي المخ. مع ذلك، قد تنتشر بعد ذلك لتصيب مناطق أكبر على كلا جانبي المخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم بمصاحبة أدوية أخرى مضادة للصرع لعلاج النوبات التَّشَنُّجية التوترية الرمعية المُعَممة (النوبات التَّشنجية الكبرى، يشمل ذلك فقدان الوعي) في المرضى المُصابين بصرع مُعَمم مجهول السبب (نوع من أنواع الصرع يُعتَقَد أن سببه وراثي).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دواء ڨيمبات </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه مادة لاكوساميد أو أي من المكونات الأخرى لهذا الدواء &nbsp;)مدرجة في القسم السادس(. إذا كنت غير متأكد من أنك مُصاب بالحساسية، الرجاء مناقشة الأمر مع الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نوع محدد من المشاكل المتعلقة بضربات القلب يُسمى الإحصار الأذيني البطيني من الدرجة الثانية أو الثالثة.</p><p dir="RTL">لا تتناول دواء ڨيمبات إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الصيدلي الخاص بك قبل تناول هذا الدَّواء.</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب قبل تناول دواء ڨيمبات في الحالات الآتية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أفكار لإيذاء نفسك أو قتلها. قد عانى عدد قليل من الأشخاص الذين يتم علاجهم بالمنتجات الدَّوائية المضادة للصَّرع مثل: لاكوساميد من أفكار لإيذاء أو قتل أنفسهم. إذا كان لديك أيٌّ من هذه الأفكار في أي وقت، فأخبر طبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة بالقلب تُؤثر على ضربات القلب لديك وغالبًا ما تعاني من ضربات قلب بطيئة على وجه الخصوص أو سريعة أو غير منتظمة (مثل: الإحصار الأذيني البطيني، الرجفان الأذيني والرفرفة الأذينية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض قلبي شديد مثل: هبوط (فشل) القلب أو كنت قد أُصبت بنوبة قلبية.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت في كثير من الأحيان تشعر بالدوخة أو تتعرَّض للسقوط. قد يجعلك دواء ڨيمبات تشعر بدوخة- وهذا قد يرفع خطر حدوث إصابة عرضية أو سقوط. هذا يعني أنه عليك توخي الحذر حتى تعتاد على تأثيرات هذا الدَّواء.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL">إذا كنت تتناول دواء فيمبات، فتحدَّث إلى طبيبك إذا كنت تتعرَّض لنوع جديد من النوبات التَّشنُّجية أو تفاقم النوبات التَّشنُّجية القائمة.</p><p dir="RTL">إذا كنت تتناول دواء ڤيمبات وتعاني من أعراض دقات قلب غير طبيعية (مثل ضربات قلب بطيئة أو سريعة أو غير منتظمة، خفقان، ضيق النفس، الشعور بالدوار، الإغماء)، فاطلب المشورة الطبية فورًا (انظر القسم 4).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong> <strong>الأقل من 4 سنوات </strong></p><p dir="RTL">لا يوصى باستعمال ڨيمبات للأطفال الذين تقل أعمارهم عن4 &nbsp;سنوات. هذا لأننا لم نعلم بعد ما إذا كان سيعمل أم لا وما إذا كان آمنًا على الأطفال في هذه الفئة العُمْرية أم لا. &nbsp;</p><p dir="RTL"><strong>تناوُل الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية التي تؤثر على القلب لديك-هذا لأنَّ دواء ڨيمبات قد يُؤثر أيضًا على القلب لديك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج مشاكل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تُزيد &quot;فاصل PR&quot; على فحص القلب (مُخَطط كهربية القلب) مثل:&nbsp; أدوية علاج الصَّرَع أو الألم التي تُسمى كاربامازيبين أو لاموترجين أو بريجابالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج أنواع معينة من عدم انتظام ضربات القلب أو فشل القلب.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL">أيضًا، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية-ذلك بسبب أنها قد تزيد أو تخفض من تأثير دواء ڨيمبات في جسمك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج العدوى الفطرية التي تُسمى فلوكونازول أو إتراكونازول أو كيتوكونازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد أدوية علاج فيروس نقص المناعة البشرية الذي يُسمى ريتونافير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج العدوى البكتيرية التي تُسمى كلاريثروميسين أو ريفامبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء عشبي يُستَخدَم لعلاج الحالات الطفيفة من القلق والاكتئاب يُسمى نبتة سانت جونز.</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا مما سبق)، تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول دواء ڨيمبات.</p><p dir="RTL"><strong>تناول</strong> <strong>دواء</strong><strong> </strong><strong>ڨيمبات</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الكحول</strong></p><p dir="RTL">كأحد احتياطات الأمان لا تتناول ڨيمبات مع الكحول.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة أو تظنين أنكِ حامل أو تخططين لإنجاب طفل، فاستشيرى طبيبكِ أو الصيدلي الخاص بكِ قبل تناول هذا الدواء.</p><p dir="RTL">يُوصى بعدم تناول دواء ڨيمبات إذا كنتِ حاملًا أو مرضعًا؛ إذ إنَّ تأثيرات دواء ڨيمبات على الحمل وعلى الجنين وعلى الطفل حديث الولادة غير معروفة. أيضًا، من غير المعروف ما إذا كان يمر دواء ڨيمبات إلى لبن الأم أم لا. اطلبي المشورة فورًا من طبيبكِ إذا أصبحتِ حاملًا أو كنت تخططين للحَمْل. سيُساعِدونك على اتخاذ قرار بشأن ما إذا كان عليكِ تناوُل دواء ڨيمبات أم لا.</p><p dir="RTL">يجب أَلَّا تتوقف عن العلاج دون التَّحدث إلى طبيبك أولًا؛ لأنَّ ذلك قد يزيد من حدوث التشنجات التي تعاني منها (النوبات التشنجية). قد يُؤدي تفاقم المرض لديكِ أيضًا إلى إلحاق الضَّرر بطفلك.</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الماكينات</strong></p><p dir="RTL">لا تمارس قيادة المركبات أو ركوب الدراجات أو تستخدم أي أدوات أو آلات حتى تعرف كيفية تأثير هذا الدَّواء عليك. هذا لأنَّ دواء ڨيمبات قد يجعلك تشعر بالدوخة أو يُسبب لك عدم وضوح بالرؤية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب دومًا تناول هذا الدواء حسب إرشادات الطبيب أو الصيدلي على نحو دقيق. كما يجب الرجوع إلى طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا تمامًا.</p><p dir="RTL"><strong>تناوُل دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول دواء ڨيمبات مرَّتين كل يوم- مرّة في الصباح وأخرى في المساء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاول أن تتناول الدواء في نفس الوقت تقريبًا من كل يوم.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع قرص دواء ڨيمبات مع كوب من الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول دواء ڨيمبات مع الطعام أو دونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ستبدأ عادة بتناول جرعة منخفضة كل يوم وسيزيد طبيبك ببطء هذه الجرعة على مدار عدة أسابيع. عندما تصل إلى الجرعة المناسبة لك، تُسمى هذه &quot;جرعة المداومة&quot;، ستتناول بعدها الكمية نفسها كل يوم. يُستخدم دواء ڨيمبات كعلاج طويل الأمد. يجب عليك الاستمرار في تناول دواء ڨيمبات إلى أن يخبرك طبيبك بالتَّوقف عن تناوله.</p><p dir="RTL"><strong>ما هي الكمية التي يجب أن تتناولها؟</strong></p><p dir="RTL">مدرج أدناه الجرعات المعتادة الموصى بها لدواء ڨيمبات للفئات العمرية والأوزان المختلفة. قد يصف لك طبيبك جرعة مختلفة إذا كنت تعاني من مشاكل بالكلى أو الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المراهقون والأطفال الذين يزنون </strong><strong>50 </strong><strong>كجم أو أكثر</strong> <strong>والبالغون</strong></p><p dir="RTL"><u>عند تناوُلك لدواء ڤيمبات بمفرده</u></p><p dir="RTL">الجرعة المبدئية المعتادة من دواء ڤيمبات هي 50 ملغ مرتين يوميًّا.</p><p dir="RTL">قد يصف لك طبيبك أيضًا جرعة مبدئية قدرها 100 ملغ&nbsp; من دواء ڤيمبات مرتين يوميًّا.</p><p dir="RTL">قد يزيد طبيبك جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغ.&nbsp; سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغ&nbsp; و300 ملغ مرتين يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عند تناول</u><u>ك</u><u> دواء ڤيمبات مع مضادات الصَّرَع الأخرى</u></p><p dir="RTL">الجرعة المبدئية المعتادة من دواء ڤيمبات هي 50 ملغ مرتين يوميًا.</p><p dir="RTL">قد يزيد الطبيب جرعتك التي تتناولها مرَّتين يوميًّا كل أسبوع بمقدار 50 ملغ، سيتم ذلك حتى تصل إلى جرعة مداومة تتراوح بين 100 ملغ و 200 &nbsp;ملغ مرتين يوميًّا.</p><p dir="RTL">إذا كنت تزن 50 كجم أو أكثر، قد يقرر طبيبك بدء العلاج بدواء ڨيمبات بجرعة &quot;تحميل&quot; مفردة قدرها 200 ملغ. سوف تبدأ بعد ذلك في تناول جرعة المداومة المستمرة الخاصَّة بك بعد 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون الذين تقل أوزانهم عن </strong><strong>50 </strong><strong>كجم</strong></p><p dir="RTL">تعتمد الجرعة على أوزان أجسامهم. يبدأ هؤلاء المرضى العلاج عادةً بتناول الشراب ولا ينتقلون إلى تناوُل الأقراص إِلَّا إذا كانوا قادرين على تناوُل الأقراص والحصول على الجرعة الصحيحة من تركيزات الأقراص المختلفة. سيصف الطبيب التركيبة الأنسب لهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من دواء ڨيمبات </strong></p><p dir="RTL">&nbsp;إذا تناولت كمية أكثر مما يجب من دواء ڨيمبات، يجب عليك الاتصال بطبيبك فورًا. لا تحاول ممارسة القيادة.</p><p dir="RTL">قد تتعرَّض لما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء (الغثيان)، أو إعياء (القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات (نوبات تشنُّجية)، مشاكل بضربات القلب مثل: ضربات القلب البطيئة أو السريعة&nbsp; أو غير المنتظمة، غيبوبة أو هبوط في ضغط الدَّم مع تسارع ضربات القلب وتعرُّق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت تناوُل دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;إذا أغفلت تناوُل جرعة خلال الست ساعات الأولى من موعد الجرعة المقرر ، فقم بتناولها بمجرد أن تتذكر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أغفلت تناوُل جرعة بعد الست ساعات الأولى من موعد الجرعة المقرر، فلا تتناول القرص الذي تم إغفاله بعد ذلك. وبدلًا من ذلك تناول دواء ڨيمبات في المرة التَّالية التي يحين فيها عادة موعد تناوله.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;إذا توقفت عن تناول دواء ڨيمبات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتوقف عن تناول دواء ڨيمبات بدون التَّحدُّث إلى طبيبك؛ نظرًا لأنَّ الصَّرع الذي تعاني منه قد يعود مرة أخرى أو يتفاقم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قرر طبيبك التَّوقف عن علاجك بدواء ڨيمبات، فسيخبرك بكيفية خفض الجرعة خطوة بخطوة.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى عن استعمال هذا الدواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب هذا الدواء في حدوث آثار جانبية على الرغم من عدم حدوث تلك الآثار الجانبية لكل من يتناوله.</p><p dir="RTL">قد تزيد الآثار الجانبية المتعلقة بالجهاز العصبي مثل الدوخة بعد تناول جرعة &quot;التحميل&quot; المفردة.</p><p dir="RTL"><strong>تحدَّث إلى طبيبك أو الصيدلي الخاص بك إذا تعرضت لأي مما يلي</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدًا</strong>: قد تؤثر<strong> </strong>في أكثر من 1 من كل 10&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بدوخة أو إعياء (غثيان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية (شفع).</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر<strong> </strong>في ما يصل إلى 1 من كل 10&nbsp;أشخاص</p><ul><li dir="RTL">هزّات قصيرة في عضلة أو مجموعة من العضلات (نوبات تشنُّجية رمعية عضلية).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في تنسيق الحركة أو المشي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في حفظ التوازن، وارتجاف &nbsp;)رعاش(، &nbsp;و نخز (شعور غير عادي بالتنميل &nbsp;او الحكة) أو تقلصات عضلية، والسقوط بسهولة والإصابة بكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالذاكرة، التفكير أو إيجاد الكلمات وارتباك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركة العينين السريعة والتي لا يمكن السيطرة عليها (رَأْرَأَة)، عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران (دوار)، شعور بالثمالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعياء (قيء) ، وجفافُ الفَم، وإمساك ، وعسر الهضم، &nbsp;وفرط الغازات في المعدة أو الأمعاء، وإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشعور أو الإحساس، صعوبة في نطق الكلمات، اضطراب في الانتباه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضجيج في الأذن مثل: الطنين، أو الرنين، أو الصفير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هياج، صعوبات النوم، اكتئاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، تعب أو ضعف (وهن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، طفح جلدي.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong>: قد تؤثر في ما يصل إلى 1 من كل 100 شخص</p><ul><li dir="RTL">بطء<strong> </strong>معدل ضربات القلب، خَفَقان، عدم انتظام النبض أو غير ذلك من التغيرات في النشاط الكهربي للقلب (اضطراب بالتَّوصيل).</li><li dir="RTL">شعور مبالغ فيه بالصحة والعافية، رؤية و/ أو سماع أشياء غير موجودة.</li><li dir="RTL">تفاعل حساسية لتناول الدواء، شرى.</li><li dir="RTL">قد تُظهِر اختبارات الدَّم اضطرابات في وظائف الكبد، الإصابات الكبدية.</li><li dir="RTL">أفكار لإيذاء نفسك أو قتلها أو محاولة الانتحار. أخبر طبيبك على الفور.</li><li dir="RTL">شعور بالغضب أو الهياج.</li><li dir="RTL">التفكير بشكل غير طبيعي أو فقدان الاتصال مع الواقع.</li><li dir="RTL">تفاعل حساسية حاد يُسبب تورمًا في الوجه أو الحلق أو اليد أو القدم أو الكاحلين أو أسفل الساقين.</li><li dir="RTL">إغماء.</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية غير طبيعية (خلل الحركة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>معروفة</strong>: لا يمكن تقدير معدل التكرار من البيانات المُتاحة</p><ul><li dir="RTL">ضربات قلب سريعة غير طبيعية (اضْطِّراب النَّظْمِ التَّسَرُّعِيّ البطيني).</li><li dir="RTL">التهاب الحَلْق، ارتفاع درجة الحرارة والإصابة بالعدوى بصورة أكثر من المُعتاد. قد تظهر اختبارات الدَّم انخفاضًا حادًا في فئة معينة من خلايا الدم البيضاء )ندرة خلايا المحببات(.</li><li dir="RTL">رد فعل جلدي حاد والذي قد يتضمن ارتفاع درجة الحرارة وأعراضًا أخرى مشابهة لأعراض الإنفلونزا ، طفح جلدى على الوجه، طفح جلدى منتشر ، تورُّم الغدد (تضخم العقد الليمفاوية). &nbsp;قد تُظهِر اختبارات الدَّم ارتفاع مستويات إنزيمات الكبد ، و أحد أنواع خلايا الدم البيضاء (كثرة خلايا اليُوزينِيَّات).</li><li dir="RTL">طفح منتشر مقرونًا ببثرات وتقشير الجلد، وخاصة حول الفم والأنف والعين والأعضاء التناسلية (متلازمة ستيفن جونسون)، وشكل أكثر حدة من الطفح يتسبب في تقشير الجلد في ما يزيد عن 30% من سطح الجسم (انحلال البشرة السام).</li><li dir="RTL">تشنجات.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الإضافية في الأطفال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>قد تُؤثر في ما يصل إلى 1 من كل 10&nbsp;أطفال</p><ul><li dir="RTL">سيلان الأنف (التهاب البلعوم الأنفي).</li><li dir="RTL">حُمى (ارتفاع درجة الحرارة)</li><li dir="RTL">التهاب الحلق (التهاب البلعوم).</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الطعام بشكل أقل من المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong>: قد تُؤثر في ما يصل إلى 1 من كل 100&nbsp;طفل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالنُّعاس أو النَّقص في الطاقة(خمول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong>: لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في السلوك، عدم التَّصرف على طبيعتهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أصبت بأي من الآثار الجانبية، فيُرجى إبلاغ الطبيب أو الصيدلي. ويشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يُمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على علبة الكرتون والشريط بعد الصيغة المختصرة EXP، يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر الموضح.</p><p dir="RTL">يُحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تُستخدم. إذ تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;المادة الفعالة هي لاكوساميد.</p><p dir="RTL">كل قرص ڨيمبات 50 ملغ يحتوي على 50 ملغ من لاكوساميد.</p><p dir="RTL">كل قرص ڨيمبات 100 ملغ يحتوي على 100 ملغ من لاكوساميد.</p><p dir="RTL">كل قرص ڨيمبات 150 ملغ يحتوي على 150 ملغ من لاكوساميد.</p><p dir="RTL">كل قرص ڨيمبات 200 ملغ يحتوي على 200 ملغ من لاكوساميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><strong>مكونات</strong><strong> </strong><strong>القرص</strong>: سيليلوز دقيق التبلور، وهيدروكسي بروبيل سيليلوز، وهيدروكسي بروبيل سيليلوز )منخفض الاستبدال(،وسيليكا غروية لامائية، وكروسبوفيدون (بولي بلازدون إكس إل-10 موافق للتصنيفات الصيدلانية).، وستيرات الماغنسيوم.</p><p dir="RTL"><strong>التغليف</strong>: كحول البولي فينيل، والبولي إيثيلين جليكول، والتلك، وثاني أكسيد التيتانيوم (E171) و ملونات .*</p><p dir="RTL"><strong>*</strong>الملونات هي:</p><p dir="RTL">أقراص 50 ملغ: أكسيد الحديد الأحمر (E172) ، و أكسيد الحديد الأسود (E172) ، ومسحة من الألومنيوم القرمزي النيلي (E132).</p><p dir="RTL">أقراص 100 ملغ: أكسيد الحديد الأصفر (E172).</p><p dir="RTL">أقراص 150 ملغ: أكسيد الحديد الأصفر (E172) ، وأكسيد الحديد الأحمر (E172) ، و أكسيد الحديد الأسود (E172)</p><p dir="RTL">أقراص 200 ملغ: مسحة من الألومنيوم القرمزي النيلي (E132).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص ڨيمبات 50 ملغ ذات لون وردي، وهي أقراص مغلفة بيضاوية الشكل بمقاس 10.4 مم &times; 4.9 مم تقريبًا منقوش عليها &lsquo;SP&rsquo; من ناحية، و&lsquo; 50 &rsquo; من الناحية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص ڨيمبات 100 ملغ ذات لون أصفر قاتم، وهي أقراص مغلفة بيضاوية الشكل بمقاس 13.2 مم &times; 6.1 مم تقريبًا منقوش عليها &lsquo;SP&rsquo; من ناحية، و&lsquo; 100 &rsquo; من الناحية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص ڨيمبات 150 ملغ ذات لون قرنفلي فاتح، وهي أقراص مغلفة بيضاوية الشكل بمقاس 15.1 مم &times; 7.0 مم تقريبًا منقوش عليها &lsquo;SP&rsquo; من ناحية، و&lsquo; 150 &rsquo; من الناحية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص ڨيمبات 200 ملغ ذات لون أزرق، وهي أقراص مغلفة بيضاوية الشكل بمقاس&nbsp; 16.6 مم &times; 7.8 مم تقريبًا منقوش عليها &lsquo;SP&rsquo; من ناحية، و&lsquo; 200 &rsquo; من الناحية الأخرى.</p><p dir="RTL">يتوفر ڨيمبات في عبوات تحتوي على 14 و56 من الأقراص المغلفة. عبوات ڨيمبات بها شرائط من البولي فينيل كلورايد/البولي فينيليدين كلورايد المغطى برقائق الألومنيوم. قد لا تتوفر جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>حق</strong><strong> </strong><strong>التفويض</strong><strong> </strong><strong>بالتسويق</strong><strong>:</strong></p><p dir="RTL">UCB Pharma S.A.,</p><p dir="RTL">All&eacute;e de la Recherche 60,</p><p dir="RTL">B‑1070 Bruxelles,</p><p dir="RTL">Belgium</p><p dir="RTL">Tel: +32 2 559 99 99</p><p dir="RTL">Fax: +32 2 559 99 00</p><p dir="RTL">http://www.ucb.com</p><p dir="RTL"><strong>Batch released by:</strong></p><p dir="RTL">Aesica Pharmaceuticals GmbH,</p><p dir="RTL">Alfred- Nobel Strasse 10,D- 40789 Monheim Am Rhein,</p><p dir="RTL">Germany</p><p>Tel: +49 2173 335 0000</p><p>Fax: +49 2173 3351020</p><p dir="RTL">info@aesica-pharma.com</p><p dir="RTL"><strong>جهة</strong><strong> </strong><strong>التصنيع</strong><strong>:</strong></p><p dir="RTL">Aesica Pharmaceuticals GmbH,</p><p dir="RTL">Galileistrase 6,</p><p dir="RTL">08056 Zwickau,</p><p dir="RTL">Germany,</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة تمت في {2021/06}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vimpat 50 mg film-coated tablets
Vimpat 100 mg film-coated tablets
Vimpat 150 mg film-coated tablets
Vimpat 200 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vimpat 50 mg film-coated tablets

Each film-coated tablet contains 50 mg lacosamide.

Vimpat 100 mg film-coated tablets

Each film-coated tablet contains 100 mg lacosamide.

Vimpat 150 mg film-coated tablets

Each film-coated tablet contains 150 mg lacosamide.

Vimpat 200 mg film-coated tablets

Each film-coated tablet contains 200 mg lacosamide.

For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet

Vimpat 50 mg film-coated tablets
Pinkish, oval film-coated tablets with approximate dimensions of 10.4 mm x 4.9 mm, and debossed with ‘SP’ on one side and ‘50’ on the other side.

Vimpat 100 mg film-coated tablets
Dark yellow, oval film-coated tablets with approximate dimensions of 13.2 mm x 6.1 mm, and debossed with ‘SP’ on one side and ‘100’ on the other side.

Vimpat 150 mg film-coated tablets
Salmon, oval film-coated tablets with approximate dimensions of 15.1 mm x 7.0 mm, and debossed with ‘SP’ on one side and ‘150’ on the other side.

Vimpat 200 mg film-coated tablets
Blue, oval film-coated tablets with approximate dimensions of 16.6 mm x 7.8 mm, and debossed with ‘SP’ on one side and ‘200’ on the other side.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vimpat is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4&nbsp;years of age with epilepsy.</p><p>Vimpat is indicated as adjunctive therapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4&nbsp;years of age with epilepsy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Lacosamide must be taken twice a day (usually once in the morning and once in the evening).</p><p>Lacosamide may be taken with or without food.</p><p>If a dose is missed, the patient should be instructed to take the missed dose immediately, and then to take the next dose of lacosamide at the regularly scheduled time. If the patient notices the missed dose within 6&nbsp;hours of the next one, he/she should be instructed to wait to take the next dose of lacosamide at the regularly scheduled time. Patients should not take a double dose.</p><p><em>&nbsp;</em></p><p><em><u>Adolescents and children </u></em><em><u>weighing 50&nbsp;kg or more, and adults</u></em></p><p>&nbsp;</p><p>The following table summarises the recommended posology for adolescents and children weighing 50&nbsp;kg or more, and for adults. More details are provided in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Monotherapy</p></td><td style="vertical-align:top"><p>Adjunctive therapy</p></td></tr><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day or 200&nbsp;mg/day</p></td><td style="vertical-align:top"><p>100&nbsp;mg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p><p>(if applicable)</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td><td style="vertical-align:top"><p>200&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td><td style="vertical-align:top"><p>50&nbsp;mg twice a day (100&nbsp;mg/day) at weekly intervals</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose</p></td><td style="vertical-align:top"><p>up to 600&nbsp;mg/day</p></td><td style="vertical-align:top"><p>up to 400&nbsp;mg/day</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Monotherapy </em><em><u>(</u></em><em>in the treatment of partial-onset seizures)</em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one&nbsp;week.</p><p>Lacosamide can also be initiated at the dose of 100&nbsp;mg twice a day based on the physician&#39;s assessment of required seizure reduction versus potential side effects.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 300&nbsp;mg twice a day (600&nbsp;mg/day).</p><p>In patients having reached a dose greater than 400&nbsp;mg/day and who need an additional antiepileptic medicinal product, the posology that is recommended for adjunctive therapy below should be followed.</p><p>&nbsp;</p><p><em>Adjunctive therapy <u>(</u>in the treatment of partial-onset seizures or in the treatment of primary generalised tonic-clonic seizures)</em></p><p>The recommended starting dose is 50&nbsp;mg twice a day which should be increased to an initial therapeutic dose of 100&nbsp;mg twice a day after one&nbsp;week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased at weekly intervals by 50&nbsp;mg twice a day (100&nbsp;mg/day), up to a maximum recommended daily dose of 400&nbsp;mg (200&nbsp;mg twice a day).</p><p><em>&nbsp;</em></p><p><em>Initiation of lacosamide treatment with a loading dose </em>(<em>initial monotherapy or conversion to monotherapy in the treatment of partial-onset seizures or adjunctive therapy</em><em> </em><em>in the treatment of partial-onset seizures or adjunctive therapy </em><em>in the treatment of primary generalised tonic-clonic seizures)</em></p><p>Lacosamide treatment may also be initiated with a single loading dose of 200&nbsp;mg, followed approximately 12&nbsp;hours later by a 100&nbsp;mg twice a day (200&nbsp;mg/day) maintenance dose regimen. Subsequent dose adjustments should be performed according to individual response and tolerability as described above. A loading dose may be initiated in patients in situations when the physician determines that rapid attainment of lacosamide steady state plasma concentration and therapeutic effect is warranted. It should be administered under medical supervision with consideration of the potential for increased incidence of serious cardiac arrhythmia and central nervous system adverse reactions (see section 4.8). Administration of a loading dose has not been studied in acute conditions such as status epilepticus.</p><p>&nbsp;</p><p><em>Discontinuation</em></p><p>In accordance with current clinical practice, if lacosamide has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200&nbsp;mg/week).</p><p>In patients who develop serious cardiac arrhythmia, clinical benefit/risk assessment should be performed and if needed lacosamide should be discontinued.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly (over 65&nbsp;years of age)</em></p><p>No dose reduction is necessary in elderly patients. Age associated decreased renal clearance with an increase in AUC levels<strong> </strong>should be considered in elderly patients (see following paragraph &lsquo;renal impairment&rsquo; and section 5.2). There is limited clinical data in the elderly patients with epilepsy, particularly at doses greater than 400&nbsp;mg/day (see sections 4.4, 4.8, and 5.1).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in mildly and moderately renally impaired adult and paediatric patients (CL<sub>CR</sub> &gt;&nbsp;30&nbsp;ml/min). In paediatric patients weighing 50&nbsp;kg or more and in adult patients with mild or moderate renal impairment a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. In paediatric patients weighing 50&nbsp;kg or more and in adult patients with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) or with end-stage renal disease, a maximum dose of 250&nbsp;mg/day is recommended and the dose titration should be performed with caution. If a loading dose is indicated, an initial dose of 100&nbsp;mg followed by a 50&nbsp;mg twice daily regimen for the first week should be used. In paediatric patients weighing less than 50&nbsp;kg with severe renal impairment (CL<sub>CR</sub> &le;&nbsp;30&nbsp;ml/min) and in those with end-stage renal disease, a reduction of 25&nbsp;% of the maximum dose is recommended. For all patients requiring haemodialysis a supplement of up to 50&nbsp;% of the divided daily dose directly after the end of haemodialysis is recommended. Treatment of patients with end-stage renal disease should be made with caution as there is little clinical experience and accumulation of a metabolite (with no known pharmacological activity).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>A maximum dose of 300&nbsp;mg/day is recommended for paediatric patients weighing 50&nbsp;kg or more and for adult patients with mild to moderate hepatic impairment.</p><p>The dose titration in these patients should be performed with caution considering co-existing renal impairment. In adolescents and adults weighing 50&nbsp;kg or more, a loading dose of 200&nbsp;mg may be considered, but further dose titration (&gt;&nbsp;200&nbsp;mg daily) should be performed with caution. Based on data in adults, in paediatric patients weighing less than 50&nbsp;kg with mild to moderate hepatic impairment, a reduction of 25&nbsp;% of the maximum dose should be applied. The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients (see section 5.2). Lacosamide should be administered to adult and paediatric patients with severe hepatic impairment only when the expected therapeutic benefits are anticipated to outweigh the possible risks. The dose may need to be adjusted while carefully observing disease activity and potential side effects in the patient.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p>The physician should prescribe the most appropriate formulation and strength according to weight and dose.</p><p>&nbsp;</p><p><em><u>Adolescents and children weighing 50&nbsp;kg or more</u></em></p><p>Dosage in adolescents and children weighing 50&nbsp;kg or more is the same as in adults (see above).</p><p>&nbsp;</p><p><em><u>C</u></em><em><u>hildren (from 4&nbsp;years of age) and adolescents weighing less than 50&nbsp;kg</u></em></p><p>The dose is determined based on body weight. It is therefore recommended to initiate treatment with the syrup and switch to tablets, if desired.</p><p><em>&nbsp;</em></p><p><em>Monotherapy (in the treatment of partial-onset seizures)</em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually increased until the optimum response is obtained. In children weighing less than 40&nbsp;kg, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 40 to under 50&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended.</p><p>&nbsp;</p><p>The following table summarises the recommended posology in monotherapy for children and adolescents weighing less than 50&nbsp;kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &lt;&nbsp;40&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;40&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Adjunctive therapy (in the treatment of partial-onset seizures or in the treatment of primary generalised tonic-clonic seizures)</em></p><p>The recommended starting dose is 2&nbsp;mg/kg/day which should be increased to an initial therapeutic dose of 4&nbsp;mg/kg/day after one week.</p><p>Depending on response and tolerability, the maintenance dose can be further increased by 2&nbsp;mg/kg/day every week. The dose should be gradually adjusted until the optimum response is obtained. In children weighing less than 20&nbsp;kg, due to an increased clearance compared to adults, a maximum dose of up to 12&nbsp;mg/kg/day is recommended. In children weighing from 20 to under 30&nbsp;kg, a maximum dose of 10&nbsp;mg/kg/day is recommended and in children weighing from 30 to under 50&nbsp;kg, a maximum dose of 8&nbsp;mg/kg/day is recommended, although in open-label studies (see sections 4.8 and 5.2), a dose up to 12&nbsp;mg/kg/day has been used by a small number of these children.</p><p>&nbsp;</p><p>The following table summarises the recommended posology in adjunctive therapy for children and adolescents weighing less than 50&nbsp;kg.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Starting dose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Single loading dose</p></td><td style="vertical-align:top"><p>Not recommended</p></td></tr><tr><td style="vertical-align:top"><p>Titration (incremental steps)</p></td><td style="vertical-align:top"><p>2&nbsp;mg/kg/day every week</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &lt;&nbsp;20&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 12&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;20&nbsp;kg to &lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 10&nbsp;mg/kg/day</p></td></tr><tr><td style="vertical-align:top"><p>Maximum recommended dose in patients &ge;&nbsp;30&nbsp;kg to &lt;&nbsp;50&nbsp;kg</p></td><td style="vertical-align:top"><p>up to 8&nbsp;mg/kg/day</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Loading dose</em></p><p>Administration of a loading dose has not been studied in children. Use of a loading dose is not recommended in adolescents and children weighing less than 50&nbsp;kg.</p><p>&nbsp;</p><p><em><u>Children less than 4&nbsp;years</u></em></p><p>The safety and efficacy of lacosamide in children aged below 4&nbsp;years have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Lacosamide film-coated tablets are for oral use. Lacosamide may be taken with or without food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Known second- or third-degree atrioventricular (AV) block. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Suicidal ideation and behaviour</u></p><p>&nbsp;</p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic medicinal products in several indications. A meta-analysis of randomised placebo-controlled studies of antiepileptic medicinal products has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for lacosamide.</p><p>Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge (see section 4.8).</p><p>&nbsp;</p><p><u>Cardiac rhythm and conduction</u></p><p>&nbsp;</p><p>Dose-related prolongations in PR interval with lacosamide have been observed in clinical studies. Lacosamide should be used with caution in patients with underlying proarrhythmic conditions such as patients with known cardiac conduction problems or severe cardiac disease (e.g. myocardial ischaemia/infarction, heart failure, structural heart disease or cardiac sodium channelopathies) or patients treated with medicinal products affecting cardiac conduction, including antiarrhythmics and sodium channel blocking antiepileptic medicinal products (see section 4.5), as well as in elderly patients.</p><p>In these patients it should be considered to perform an ECG before a lacosamide dose increase above 400&nbsp;mg/day and after lacosamide is titrated to steady-state.</p><p>&nbsp;</p><p>In the placebo-controlled studies of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however, both have been reported in open-label epilepsy studies and in post-marketing experience.</p><p>&nbsp;</p><p>In post-marketing experience, AV block (including second degree or higher AV block) has been reported. In patients with proarrhythmic conditions, ventricular tachyarrhythmia has been reported. In rare cases, these events have led to asystole, cardiac arrest and death in patients with underlying proarrhythmic conditions.</p><p>&nbsp;</p><p>Patients should be made aware of the symptoms of cardiac arrhythmia (e.g. slow, rapid or irregular pulse, palpitations, shortness of breath, feeling lightheaded, fainting). Patients should be counselled to seek immediate medical advice if these symptoms occur.</p><p><u>&nbsp;</u></p><p><u>Dizziness</u></p><p>&nbsp;</p><p>Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine (see section 4.8).</p><p>&nbsp;</p><p><u>Potential for new onset or worsening of myoclonic seizures</u></p><p>&nbsp;</p><p>New onset or worsening of myoclonic seizures has been reported in both adult and paediatric patients with PGTCS, in particular during titration. In patients with more than one seizure type, the observed benefit of control for one seizure type should be weighed against any observed worsening in another seizure type.</p><p><u>&nbsp;</u></p><p><u>Potential for electro-clinical worsening in specific paediatric epilepsy syndromes</u></p><p>&nbsp;</p><p>The safety and efficacy of lacosamide in paediatric patients with epilepsy syndromes in which focal and generalised seizures may coexist have not been determined.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lacosamide should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (including sodium channel blocking antiepileptic medicinal products) and in patients treated with antiarrhythmics. However, subgroup analysis in clinical studies did not identify an increased magnitude of PR prolongation in patients with concomitant administration of carbamazepine or lamotrigine.</p><p>&nbsp;</p><p><em><u>In vitro</u></em><u> data</u></p><p>&nbsp;</p><p>Data generally suggest that lacosamide has a low interaction potential. <em>In vitro</em> studies indicate that the enzymes CYP1A2, CYP2B6, and CYP2C9 are not induced and that CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP2E1 are not inhibited by lacosamide at plasma concentrations observed in clinical studies. An <em>in vitro</em> study indicated that lacosamide is not transported by P‑glycoprotein in the intestine. <em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite.</p><p>&nbsp;</p><p><em><u>In vivo</u></em><u> data</u></p><p>&nbsp;</p><p>Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent. Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given 200&nbsp;mg twice a day), but C<sub>max</sub> of midazolam was slightly increased (30&nbsp;%). Lacosamide did not affect the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given 300&nbsp;mg twice a day).</p><p>The CYP2C19 inhibitor omeprazole (40&nbsp;mg once daily) did not give rise to a clinically significant change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent.</p><p>Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g. fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead to increased systemic exposure of lacosamide. Such interactions have not been established <em>in vivo,</em> but are possible based on <em>in vitro</em> data.</p><p>&nbsp;</p><p>Strong enzyme inducers such as rifampicin or St&nbsp;John&rsquo;s wort (Hypericum perforatum) may moderately reduce the systemic exposure of lacosamide. Therefore, starting or ending treatment with these enzyme inducers should be done with caution.</p><p>&nbsp;</p><p><u>Antiepileptic medicinal products </u></p><p>&nbsp;</p><p>In interaction studies lacosamide did not significantly affect the plasma concentrations of carbamazepine and valproic acid. Lacosamide plasma concentrations were not affected by carbamazepine and by valproic acid. Population pharmacokinetic analyses in different age groups estimated that concomitant treatment with other antiepileptic medicinal products known to be enzyme inducers (carbamazepine, phenytoin, phenobarbital, in various doses) decreased the overall systemic exposure of lacosamide by 25&nbsp;% in adults and 17&nbsp;% in paediatric patients.</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>In an interaction study there was no clinically relevant interaction between lacosamide and the oral contraceptives ethinylestradiol and levonorgestrel. Progesterone concentrations were not affected when the medicinal products were co-administered.</p><p>&nbsp;</p><p><u>Others</u></p><p>&nbsp;</p><p>Interaction studies showed that lacosamide had no effect on the pharmacokinetics of digoxin. There was no clinically relevant interaction between lacosamide and metformin.</p><p>Co-administration of warfarin with lacosamide does not result in a clinically relevant change in the pharmacokinetics and pharmacodynamics of warfarin.</p><p>Although no pharmacokinetic data on the interaction of lacosamide with alcohol are available, a pharmacodynamic effect cannot be excluded.</p><p>Lacosamide has a low protein binding of less than 15&nbsp;%. Therefore, clinically relevant interactions with other medicinal products through competition for protein binding sites are considered unlikely.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>&nbsp;</em></p><p><em>Risk related to epilepsy and antiepileptic medicinal products in general </em></p><p>For all antiepileptic medicinal products, it has been shown that in the offspring of treated women with epilepsy, the prevalence of malformations is two to three times greater than the rate of approximately 3&nbsp;% in the general population. In the treated population, an increase in malformations has been noted with polytherapy, however, the extent to which the treatment and/or the illness is responsible has not been elucidated.</p><p>Moreover, effective antiepileptic therapy must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.</p><p>&nbsp;</p><p><em>Risk related to lacosamide</em></p><p>There are no adequate data from the use of lacosamide in pregnant women. Studies in animals did not indicate any teratogenic effects in rats or rabbits, but embryotoxicity was observed in rats and rabbits at maternal toxic doses (see section 5.3). The potential risk for humans is unknown.</p><p>Lacosamide should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus). If women decide to become pregnant, the use of this product should be carefully re-evaluated.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>It is unknown whether lacosamide is excreted in human breast milk. A risk to the newborns/infants cannot be excluded. Animal studies have shown excretion of lacosamide in breast milk. For precautionary measures, breast-feeding should be discontinued during treatment with lacosamide.</p><p><strong>&nbsp;</strong></p><p><u>Fertility</u></p><p>&nbsp;</p><p>No adverse reactions on male or female fertility or reproduction were observed in rats at doses producing plasma exposures (AUC) up to approximately 2&nbsp;times the plasma AUC in humans at the maximum recommended human dose (MRHD).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lacosamide has minor to moderate influence on the ability to drive and use machines. Lacosamide treatment has been associated with dizziness or blurred vision.</p><p>Accordingly, patients should be advised not to drive or to operate other potentially hazardous machinery until they are familiar with the effects of lacosamide on their ability to perform such activities.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>Based on the analysis of pooled placebo-controlled clinical studies in adjunctive therapy in 1,308&nbsp;patients with partial-onset seizures, a total of 61.9&nbsp;% of patients randomised to lacosamide and 35.2&nbsp;% of patients randomised to placebo reported at least 1&nbsp;adverse reaction. The most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) with lacosamide treatment were dizziness, headache, nausea and diplopia. They were usually mild to moderate in intensity. Some were dose-related and could be alleviated by reducing the dose. Incidence and severity of central nervous system (CNS) and gastrointestinal (GI) adverse reactions usually decreased over time.</p><p>In all of these controlled studies, the discontinuation rate due to adverse reactions was 12.2&nbsp;% for patients randomised to lacosamide and 1.6&nbsp;% for patients randomised to placebo. The most common adverse reaction resulting in discontinuation of lacosamide therapy was dizziness.</p><p>Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose.</p><p>&nbsp;</p><p>Based on the analysis of data from a non-inferiority monotherapy clinical study comparing lacosamide to carbamazepine controlled release (CR), the most frequently reported adverse reactions (&ge;&nbsp;10&nbsp;%) for lacosamide were headache and dizziness. The discontinuation rate due to adverse reactions was 10.6&nbsp;% for patients treated with lacosamide and 15.6&nbsp;% for patients treated with carbamazepine CR.</p><p>&nbsp;</p><p>The safety profile of lacosamide reported in a study conducted in patients aged 4&nbsp;years and older with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures (PGTCS) was consistent with the safety profile reported from the pooled placebo-controlled clinical studies in partial-onset seizures. Additional adverse reactions reported in PGTCS patients were myoclonic epilepsy (2.5&nbsp;% in the lacosamide-group and 0&nbsp;% in the placebo-group) and ataxia (3.3&nbsp;% in the lacosamide-group and 0&nbsp;% in the placebo-group). The most frequently reported adverse reactions were dizziness and somnolence. The most common adverse reactions resulting in discontinuation of lacosamide therapy were dizziness and suicidal ideation. The discontinuation rate due to adverse reactions was 9.1&nbsp;% in the lacosamide group and 4.1&nbsp;% in the placebo group.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The table below shows the frequencies of adverse reactions which have been reported in clinical studies and post-marketing experience. The frequencies are defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100) and not known (frequency cannot be estimated from available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Blood and lymphatic disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug hypersensitivity<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)<sup> (1,2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Confusional state Insomnia<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Aggression</p><p>Agitation<sup>(1)</sup></p><p>Euphoric mood<sup>(1)</sup></p><p>Psychotic disorder<sup>(1)</sup></p><p>Suicide attempt<sup> (1)</sup></p><p>Suicidal ideation</p><p>Hallucination<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myoclonic seizures<sup>(3)</sup></p><p>Ataxia</p><p>Balance disorder</p><p>Memory impairment</p><p>Cognitive disorder</p><p>Somnolence</p><p>Tremor</p><p>Nystagmus</p><p>Hypoesthesia</p><p>Dysarthria</p><p>Disturbance in attention</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Syncope<sup>(2)</sup></p><p>Coordination abnormal</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Convulsion</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Atrioventricular block<sup>(1,2)</sup></p><p>Bradycardia<sup>(1,2)</sup></p><p>Atrial Fibrillation <sup>(1,2)</sup></p><p>Atrial Flutter <sup>(1,2)</sup></p></td><td style="vertical-align:top"><p>Ventricular tachyarrhythmia <sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Constipation</p><p>Flatulence</p><p>Dyspepsia</p><p>Dry mouth</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal<sup>(2)</sup></p><p>Hepatic enzyme increased (&gt;&nbsp;2x&nbsp;ULN)<sup> (1)</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus</p><p>Rash<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>(1)</sup></p><p>Urticaria<sup>(1)</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome<sup>(1)</sup></p><p>Toxic epidermal necrolysis<sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gait disturbance</p><p>Asthenia</p><p>Fatigue</p><p>Irritability</p><p>Feeling drunk</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p><p>Skin laceration</p><p>Contusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>(1) </sup>Adverse reactions reported in post marketing experience.</p><p><sup>(2)</sup> See Description of selected adverse reactions.</p><p><sup>(3)</sup> Reported in PGTCS studies.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>The use of lacosamide is associated with dose-related increase in the PR interval. Adverse reactions associated with PR interval prolongation (e.g. atrioventricular block, syncope, bradycardia) may occur.</p><p>In adjunctive clinical studies in epilepsy patients, the incidence rate of reported first-degree AV Block is uncommon, 0.7&nbsp;%, 0&nbsp;%, 0.5&nbsp;% and 0&nbsp;%<strong> </strong>for lacosamide 200&nbsp;mg, 400&nbsp;mg, 600&nbsp;mg or placebo, respectively. No second- or higher degree AV Block was seen in these studies. However, cases with second- and third-degree AV Block associated with lacosamide treatment have been reported in post‑marketing experience. In the monotherapy clinical study comparing lacosamide to carbamazepine CR, the extent of increase in PR interval was comparable between lacosamide and carbamazepine.</p><p>The incidence rate for syncope reported in pooled adjunctive therapy clinical studies is uncommon and did not differ between lacosamide (n=944) treated epilepsy patients (0.1&nbsp;%) and placebo (n=364) treated epilepsy patients (0.3&nbsp;%). In the monotherapy clinical study comparing lacosamide to carbamazepine CR, syncope was reported in 7/444 (1.6&nbsp;%) lacosamide patients and in 1/442 (0.2&nbsp;%) carbamazepine CR patients.</p><p>Atrial fibrillation or flutter were not reported in short term clinical studies; however, both have been reported in open-label epilepsy studies and in post-marketing experience.</p><p>&nbsp;</p><p><em>Laboratory abnormalities</em></p><p>Abnormalities in liver function tests have been observed in placebo-controlled studies with lacosamide in adult patients with partial-onset seizures who were taking 1 to 3 concomitant antiepileptic medicinal products. Elevations of ALT to &ge;&nbsp;3x&nbsp;ULN occurred in 0.7&nbsp;% (7/935) of Vimpat patients and 0&nbsp;% (0/356) of placebo patients.</p><p><u>&nbsp;</u></p><p><em>Multiorgan hypersensitivity reactions</em></p><p>Multiorgan hypersensitivity reactions (also known as Drug Reaction with Eosinophilia and Systemic Symptoms, DRESS) have been reported in patients treated with some antiepileptic medicinal products. These reactions are variable in expression, but typically present with fever and rash and can be associated with involvement of different organ systems. If multiorgan hypersensitivity reaction is suspected, lacosamide should be discontinued.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The safety profile of lacosamide in placebo-controlled (see study details in section 5.1) and in open-label studies (n=408) in adjunctive therapy in children from 4&nbsp;years of age with partial-onset seizures was consistent with the safety profile observed in adults although the frequency of some adverse reactions (somnolence, vomiting and convulsion) was increased and additional adverse reactions (nasopharyngitis, pyrexia, pharyngitis, decreased appetite, lethargy and abnormal behaviour) have been reported in paediatric patients: nasopharyngitis (15.7&nbsp;%), vomiting (14.7&nbsp;%), somnolence (14.0&nbsp;%), dizziness (13.5&nbsp;%), pyrexia (13.0&nbsp;%), convulsion (7.8&nbsp;%), decreased appetite (5.9&nbsp;%), pharyngitis (4.7&nbsp;%), lethargy (2.7&nbsp;%) and abnormal behaviour (1.7&nbsp;%).</p><p>A total of 67.8&nbsp;% of patients randomised to lacosamide and 58.1&nbsp;% of patients randomised to placebo reported at least 1 adverse reaction.</p><p>Behavioural, cognition and emotional functioning were measured by the questionnaires Achenbach CBCL and BRIEF that were applied at baseline and throughout the studies and were mainly stable during the course of the studies.</p><p>&nbsp;</p><p><u>Elderly population </u></p><p><u>&nbsp;</u></p><p>In the monotherapy study comparing lacosamide to carbamazepine CR, the types of adverse reactions related to lacosamide in elderly patients (&ge;&nbsp;65&nbsp;years of age) appear to be similar to that observed in patients less than 65&nbsp;years of age. However, a higher incidence (&ge;&nbsp;5&nbsp;% difference) of fall, diarrhoea and tremor has been reported in elderly patients compared to younger adult patients. The most frequent cardiac-related adverse reaction reported in elderly compared to the younger adult population was first-degree AV block. This was reported with lacosamide in 4.8&nbsp;% (3/62) in elderly patients versus 1.6&nbsp;% (6/382) in younger adult patients. The discontinuation rate due to adverse events observed with lacosamide was 21.0&nbsp;% (13/62) in elderly patients versus 9.2&nbsp;% (35/382) in younger adult patients. These differences between elderly and younger adult patients were similar to those observed in the active comparator group.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong><em>Saudi Arabia:</em></strong></p><p>&nbsp;</p><p>-&nbsp; &nbsp;The National Pharmacovigilance Safety Centre (NPC)</p><p>&nbsp;</p><p>o Toll free phone: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong><em>Other GCC States:</em></strong></p><p>&nbsp;</p><p>-&nbsp; &nbsp;Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.9&nbsp;&nbsp;&nbsp; Overdose</strong></p><p>&nbsp;</p><p><u>Symptoms</u></p><p><em>&nbsp;</em></p><p>Symptoms observed after an accidental or intentional overdose of lacosamide are primarily associated with CNS and gastrointestinal system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The types of adverse reactions experienced by patients exposed to doses above 400&nbsp;mg up to 800&nbsp;mg were not clinically different from those of patients administered recommended doses of lacosamide.</p><ul><li>Reactions reported after an intake of more than 800&nbsp;mg are dizziness, nausea, vomiting, seizures (generalised tonic-clonic seizures, status epilepticus). Cardiac conduction disorders, shock and coma have also been observed. Fatalities have been reported in patients following an intake of acute single overdose of several grams of lacosamide.</li></ul><p>&nbsp;</p><p><u>Management</u></p><p>&nbsp;</p><p>There is no specific antidote for overdose with lacosamide. Treatment of lacosamide overdose should include general supportive measures and may include haemodialysis if necessary (see section 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX18</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The active substance, lacosamide (R‑2‑acetamido‑N‑benzyl‑3‑methoxypropionamide) is a functionalised amino acid.</p><p>The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated. <em>In vitro</em> electrophysiological studies have shown that lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes.<s> </s></p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Lacosamide protected against seizures in a broad range of animal models of partial and primary generalised seizures and delayed kindling development.</p><p>In non-clinical experiments lacosamide in combination with levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, topiramate or gabapentin showed synergistic or additive anticonvulsant effects.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety (</u><u>partial-onset seizures)</u></p><p><u>Adult population</u></p><p><em>&nbsp;</em></p><p><em>Monotherapy</em></p><p>Efficacy of lacosamide as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine CR in 886 patients 16&nbsp;years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial-onset seizures with or without secondary generalisation. The patients were randomised to carbamazepine CR or lacosamide, provided as tablets, in a 1:1 ratio. The dose was based on dose-response and ranged from 400 to 1,200&nbsp;mg/day for carbamazepine CR and from 200 to 600&nbsp;mg/day for lacosamide. The duration of the treatment was up to 121&nbsp;weeks depending on the response.</p><p>The estimated 6-month seizure freedom rates were 89.8&nbsp;% for lacosamide-treated patients and 91.1&nbsp;% for carbamazepine CR treated patients using the Kaplan-Meier survival analysis method. The adjusted absolute difference between treatments was -1.3&nbsp;% (95&nbsp;% CI: -5.5, 2.8). The Kaplan-Meier estimates of 12-month seizure freedom rates were 77.8&nbsp;% for lacosamide-treated patients and 82.7&nbsp;% for carbamazepine CR treated patients.</p><p>The 6-month seizure freedom rates in elderly patients of 65 and above (62&nbsp;patients in lacosamide, 57&nbsp;patients in carbamazepine CR) were similar between both treatment groups. The rates were also similar to those observed in the overall population. In the elderly population, the maintenance lacosamide dose was 200&nbsp;mg/day in 55&nbsp;patients (88.7&nbsp;%), 400&nbsp;mg/day in 6&nbsp;patients (9.7&nbsp;%) and the dose was escalated to over 400&nbsp;mg/day in 1&nbsp;patient (1.6&nbsp;%).</p><p>&nbsp;</p><p><em>Conversion to monotherapy</em></p><p>The efficacy and safety of lacosamide in conversion to monotherapy has been assessed in a historical-controlled, multicentre, double-blind, randomised trial. In this study, 425 patients aged 16 to 70&nbsp;years with uncontrolled partial-onset seizures taking stable doses of 1 or 2 marketed antiepileptic medicinal products were randomised to be converted to lacosamide monotherapy (either 400&nbsp;mg/day or 300&nbsp;mg/day in a 3:1 ratio). In treated patients who completed titration and started withdrawing antiepileptic medicinal products (284 and 99 respectively), monotherapy was maintained in 71.5&nbsp;% and 70.7&nbsp;% of patients respectively for 57-105&nbsp;days (median 71&nbsp;days), over the targeted observation period of 70&nbsp;days.</p><p>&nbsp;</p><p><strong><em>Adjunctive therapy</em></strong></p><p><strong>The efficacy of lacosamide as adjunctive therapy at recommended doses (200&nbsp;mg/day, 400&nbsp;mg/day) was established in 3 multicenter, randomised, placebo-controlled clinical studies with a 12-week maintenance period. Lacosamide 600&nbsp;mg/day was also shown to be effective in controlled adjunctive therapy studies, although the efficacy was similar to 400&nbsp;mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions. Thus, the 600&nbsp;mg/day dose is not recommended. The maximum recommended dose is 400&nbsp;mg/day. These studies, involving 1,308&nbsp;patients with a history of an average of 23&nbsp;years of partial-onset seizures, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with 1‑3 </strong>antiepileptic medicinal products <strong>in patients with uncontrolled partial-onset seizures with or without secondary generalisation. </strong>Overall the proportion of subjects with a 50&nbsp;% reduction in seizure frequency was 23&nbsp;%, 34&nbsp;%, and 40&nbsp;% for placebo, lacosamide 200&nbsp;mg/day and lacosamide 400&nbsp;mg/day.</p><p>&nbsp;</p><p><strong>The pharmacokinetics and safety of a single loading dose of intravenous lacosamide were determined in a multicenter, open-label study designed to assess the safety and tolerability of rapid initiation of lacosamide using a single intravenous loading dose (including 200</strong>&nbsp;<strong>mg) followed by twice daily oral dosing (equivalent to the intravenous dose) as adjunctive therapy in adult subjects 16 to 60&nbsp;years of age with partial-onset seizures. </strong></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Partial-onset seizures have a similar clinical expression in children from 4&nbsp;years of age and in adults. The efficacy of lacosamide in children aged 4&nbsp;years and older has been extrapolated from data of adolescents and adults with partial-onset seizures, for whom a similar response was expected provided the paediatric dose adaptations are established (see section 4.2) and safety has been demonstrated (see section 4.8).</p><p>The efficacy supported by the extrapolation principle stated above was confirmed by a double-blind, randomised, placebo-controlled study. The study consisted of an 8-week baseline period followed by a 6-week titration period. Eligible patients on a stable dose regimen of 1 to &le;&nbsp;3&nbsp;antiepileptic medicinal products, who still experienced at least 2&nbsp;partial-onset seizures during the 4&nbsp;weeks prior to screening with seizure-free phase no longer than 21&nbsp;days in the 8-week period prior to entry into the baseline period, were randomised to receive either placebo (n=172) or lacosamide (n=171).</p><p>Dosing was initiated at a dose of 2&nbsp;mg/kg/day in subjects weighing less than 50&nbsp;kg or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more in 2 divided doses. During the titration period, lacosamide doses were adjusted in 1or 2&nbsp;mg/kg/day increments in subjects weighing less than 50&nbsp;kg or 50 or 100&nbsp;mg/day in subjects weighing 50&nbsp;kg or more at weekly intervals to achieve the target maintenance period dose range.</p><p>Subjects must have achieved the minimum target dose for their body weight category for the final 3&nbsp;days of the titration period to be eligible for entry into the 10-week maintenance period. Subjects were to remain on stable lacosamide dose throughout the maintenance period or were withdrawn and entered in the blinded taper period.</p><p>Statistically significant (p=0.0003) and clinically relevant reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was observed between the lacosamide and the placebo group. The percent reduction over placebo based on analysis of covariance was 31.72&nbsp;% (95&nbsp;% CI: 16.342, 44.277).</p><p>Overall, the proportion of subjects with at least a 50&nbsp;% reduction in partial-onset seizure frequency per 28&nbsp;days from baseline to the maintenance period was 52.9&nbsp;% in the lacosamide group compared with 33.3&nbsp;% in the placebo group.</p><p>The quality of life assessed by the Pediatric Quality of Life Inventory indicated that subjects in both lacosamide and placebo groups had a similar and stable health-related quality of life during the entire treatment period.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety (primary generalized tonic-clonic seizures)</u></p><p>&nbsp;</p><p>The efficacy of lacosamide as adjunctive therapy in patients 4&nbsp;years of age and older with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic seizures (PGTCS) was established in a 24-week double-blind, randomized, placebo-controlled, parallel-group, multi-center study. The study consisted of a 12-week historical baseline period, a 4-week prospective baseline period and a 24-week treatment period (which included a 6-week titration period and an 18-week maintenance period). Eligible patients on a stable dose of 1 to 3 antiepileptic drugs experiencing at least 3 documented PGTCS during the 16-week combined baseline period were randomized 1 to 1 to receive lacosamide or placebo (patients in the full analysis set: lacosamide n=118, placebo n=121; of them 8 patients in the &ge;&nbsp;4 to &lt;&nbsp;12&nbsp;years age group and 16 patients in the &ge;&nbsp;12 to &lt;&nbsp;18&nbsp;years range were treated with lacosamide and 9 and 16 patients, respectively with placebo).</p><p>Patients were titrated up to the target maintenance period dose of 12&nbsp;mg/kg/day in patients weighing less than 30&nbsp;kg, 8&nbsp;mg/kg/day in patients weighing from 30 to less than 50&nbsp;kg or 400&nbsp;mg/day in patients weighing 50&nbsp;kg or more.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td style="vertical-align:bottom"><p>Efficacy variable</p><p>Parameter</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=121</p></td><td style="vertical-align:top"><p>Lacosamide</p><p>N=118</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p>Time to second PGTCS</p></td></tr><tr><td style="vertical-align:top"><p>Median (days)</p></td><td style="vertical-align:top"><p>77.0</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>95&nbsp;% CI</p></td><td style="vertical-align:top"><p>49.0, 128.0</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Lacosamide &ndash; Placebo</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio</p></td><td colspan="2" style="vertical-align:top"><p>0.540</p></td></tr><tr><td style="vertical-align:top"><p>95&nbsp;% CI</p></td><td colspan="2" style="vertical-align:top"><p>0.377, 0.774</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Seizure freedom</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Stratified Kaplan-Meier estimate (%)</p></td><td style="vertical-align:top"><p>17.2</p></td><td style="vertical-align:top"><p>31.3</p></td></tr><tr><td style="vertical-align:top"><p>95&nbsp;% CI</p></td><td style="vertical-align:top"><p>10.4, 24.0</p></td><td style="vertical-align:top"><p>22.8, 39.9</p></td></tr><tr><td style="vertical-align:top"><p>Lacosamide &ndash; Placebo</p></td><td colspan="2" style="vertical-align:top"><p>14.1</p></td></tr><tr><td style="vertical-align:top"><p>95&nbsp;% CI</p></td><td colspan="2" style="vertical-align:top"><p>3.2, 25.1</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.011</p></td></tr></tbody></table><p>Note: For the lacosamide group, the median time to second PGTCS could not be estimated by Kaplan-Meier methods because ˃&nbsp;50% of patients did not experience a second PGTCS by Day&nbsp;166.</p><p>&nbsp;</p><p>The findings in the paediatric subgroup were consistent with the results of the overall population for the primary, secondary and other efficacy endpoints.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption </u></p><p>&nbsp;</p><p>Lacosamide is rapidly and completely absorbed after oral administration. The oral bioavailability of lacosamide tablets is approximately 100&nbsp;%. Following oral administration, the plasma concentration of unchanged lacosamide increases rapidly and reaches C<sub>max</sub> about 0.5 to 4&nbsp;hours post-dose. Vimpat tablets and oral syrup are bioequivalent. Food does not affect the rate and extent of absorption.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution is approximately 0.6&nbsp;L/kg. Lacosamide is less than 15&nbsp;% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>95&nbsp;% of the dose is excreted in the urine as lacosamide and metabolites. The metabolism of lacosamide has not been completely characterised.</p><p>The major compounds excreted in urine are unchanged lacosamide (approximately 40&nbsp;% of the dose) and its O‑desmethyl metabolite less than 30&nbsp;%.</p><p>A polar fraction proposed to be serine derivatives accounted for approximately 20&nbsp;% in urine, but was detected only in small amounts (0‑2&nbsp;%) in human plasma of some subjects. Small amounts (0.5‑2&nbsp;%) of additional metabolites were found in the urine.</p><p><em>In vitro</em> data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O‑desmethyl metabolite but the main contributing isoenzyme has not been confirmed<em> in vivo</em>. No clinically relevant difference in lacosamide exposure was observed comparing its pharmacokinetics in extensive metabolisers (EMs, with a functional CYP2C19) and poor metabolisers (PMs, lacking a functional CYP2C19). Furthermore an interaction study with omeprazole (CYP2C19‑inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor. The plasma concentration of O‑desmethyl‑lacosamide is approximately 15&nbsp;% of the concentration of lacosamide in plasma. This major metabolite has no known pharmacological activity.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Lacosamide is primarily eliminated from the systemic circulation by renal excretion and biotransformation. After oral and intravenous administration of radiolabeled lacosamide, approximately 95&nbsp;% of radioactivity administered was recovered in the urine and less than 0.5&nbsp;% in the faeces. The elimination half-life of lacosamide is approximately 13&nbsp;hours. The pharmacokinetics is dose-proportional and constant over time, with low intra- and inter-subject variability. Following twice daily dosing, steady state plasma concentrations are achieved after a 3&nbsp;day period. The plasma concentration increases with an accumulation factor of approximately 2.</p><p><u>&nbsp;</u></p><p>A single loading dose of 200&nbsp;mg approximates steady-state concentrations comparable to 100&nbsp;mg twice daily oral administration.</p><p><u>&nbsp;</u></p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p><em>Gender</em></p><p>Clinical studies indicate that gender does not have a clinically significant influence on the plasma concentrations of lacosamide.</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>The AUC of lacosamide was increased by approximately 30&nbsp;% in mildly and moderately and 60&nbsp;% in severely renal impaired patients and patients with end-stage renal disease requiring haemodialysis compared to healthy subjects, whereas C<sub>max</sub> was unaffected.</p><p>Lacosamide is effectively removed from plasma by haemodialysis. Following a 4‑hour haemodialysis treatment, AUC of lacosamide is reduced by approximately 50&nbsp;%. Therefore, dosage supplementation following haemodialysis is recommended (see section 4.2). The exposure of the O‑desmethyl metabolite was several-fold increased in patients with moderate and severe renal impairment. In absence of haemodialysis in patients with end-stage renal disease, the levels were increased and continuously rising during the 24‑hour sampling. It is unknown whether the increased metabolite exposure in end-stage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.</p><p><u>&nbsp;</u></p><p><em>Hepatic impairment</em></p><p>Subjects with moderate hepatic impairment (Child-Pugh B) showed higher plasma concentrations of lacosamide (approximately 50&nbsp;% higher AUC<sub>norm</sub>). The higher exposure was partly due to a reduced renal function in the studied subjects. The decrease in non-renal clearance in the patients of the study was estimated to give a 20&nbsp;% increase in the AUC of lacosamide. The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment (see section 4.2).</p><p><u>&nbsp;</u></p><p><em>Elderly (over 65&nbsp;years of age)</em></p><p>In a study in elderly men and women including 4&nbsp;patients &gt;&nbsp;75&nbsp;years of age, AUC was about 30 and 50&nbsp;% increased compared to young men, respectively. This is partly related to lower body weight. The body weight normalized difference is 26 and 23&nbsp;%, respectively. An increased variability in exposure was also observed. The renal clearance of lacosamide was only slightly reduced in elderly subjects in this study.</p><p>A general dose reduction is not considered to be necessary unless indicated due to reduced renal function (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The paediatric pharmacokinetic profile of lacosamide was determined in a population pharmacokinetic analysis using sparse plasma concentration data obtained in one placebo-controlled randomised study and three open-label studies in 414&nbsp;children with epilepsy aged 6&nbsp;months to 17&nbsp;years. The administered lacosamide doses ranged from 2 to 17.8&nbsp;mg/kg/day in twice daily intake, with a maximum of 600&nbsp;mg/day for children weighing 50&nbsp;kg or more.</p><p>The typical plasma clearance was estimated to be 1.04&nbsp;L/h, 1.32&nbsp;L/h and 1.86&nbsp;L/h for children weighing 20&nbsp;kg, 30&nbsp;kg and 50&nbsp;kg respectively. In comparison, plasma clearance was estimated at 1.92&nbsp;L/h in adults (70&nbsp;kg body weight).</p><p>Population pharmacokinetic analysis using sparse pharmacokinetic samples from PGTCS study showed a similar exposure in patients with PGTCS and in patients with partial-onset seizures.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure.</p><p>A safety pharmacology study with intravenous administration of lacosamide in anesthetised dogs showed transient increases in PR interval and QRS complex duration and decreases in blood pressure most likely due to a cardiodepressant action. These transient changes started in the same concentration range as after maximum recommended clinical dosing. In anesthetised dogs and Cynomolgus monkeys, at intravenous doses of 15-60&nbsp;mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen.</p><p>In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure. These changes included an increased organ weight, hypertrophy of hepatocytes, increases in serum concentrations of liver enzymes and increases in total cholesterol and triglycerides. Apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed.</p><p>In reproductive and developmental toxicity studies in rodents and rabbits, no teratogenic effects but an increase in numbers of stillborn pups and pup deaths in the peripartum period, and slightly reduced live litter sizes and pup body weights were observed at maternal toxic doses in rats corresponding to systemic exposure levels similar to the expected clinical exposure. Since higher exposure levels could not be tested in animals due to maternal toxicity, data are insufficient to fully characterise the embryofetotoxic and teratogenic potential of lacosamide.</p><p>Studies in rats revealed that lacosamide and/or its metabolites readily crossed the placental barrier.</p><p>In juvenile rats and dogs, the types of toxicity do not differ qualitatively from those observed in adult animals. In juvenile rats, a reduced body weight was observed at systemic exposure levels similar to the expected clinical exposure. In juvenile dogs, transient and dose-related CNS clinical signs started to be observed at systemic exposure levels below the expected clinical exposure.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>microcrystalline cellulose</p><p>hydroxypropylcellulose</p><p>hydroxypropylcellulose (low substituted)</p><p>silica, colloidal, anhydrous</p><p>crospovidone (polyplasdone XL-10 Pharmaceutical Grade)</p><p>magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coat</u></p><p>&nbsp;</p><p><em><u>Vimpat 50&nbsp;mg film-coated tablets</u></em></p><p>&nbsp;</p><p>polyvinyl alcohol</p><p>polyethylene glycol 3350</p><p>talc</p><p>titanium dioxide (E171)</p><p>red iron oxide (E172)</p><p>black iron oxide (E172)</p><p>indigo carmine aluminium lake (E132)</p><p>&nbsp;</p><p><em><u>Vimpat 100&nbsp;mg film-coated tablets</u></em></p><p>&nbsp;</p><p>polyvinyl alcohol</p><p>polyethylene glycol 3350</p><p>talc</p><p>titanium dioxide (E171)</p><p>yellow iron oxide (E172)</p><p>&nbsp;</p><p><em><u>Vimpat 150&nbsp;mg film-coated tablets</u></em></p><p>&nbsp;</p><p>polyvinyl alcohol</p><p>polyethylene glycol 3350</p><p>talc</p><p>titanium dioxide (E171)</p><p>yellow iron oxide (E172),<em> </em>red iron oxide (E172), black iron oxide (E172)</p><p>&nbsp;</p><p><em><u>Vimpat 200&nbsp;mg film-coated tablets</u></em></p><p>&nbsp;</p><p>polyvinyl alcohol</p><p>polyethylene glycol 3350</p><p>talc</p><p>titanium dioxide (E171)</p><p>indigo carmine aluminium lake (E132)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

5 years.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vimpat 50&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>Packs of 14,&nbsp; and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.</p><p>&nbsp;</p><p><u>Vimpat 100&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>Packs of 14and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.</p><p>&nbsp;</p><p><u>Vimpat 150&nbsp;mg film-coated tablets</u></p><p>&nbsp;</p><p>Packs of 14and 56 film-coated tablets in PVC/PVDC blister sealed with an aluminium foil.</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                UCB Pharma S.A.
Allée de la Recherche 60
B 1070 Bruxelles
Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                DATE OF REVISION OF THE TEXT 06/2021

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>